Jupiter Life Line Hospitals Q2 Results FY27 Preview: Results Date, Expectations and the Numbers That Will Decide the September 2026 Quarter
- September 16, 2026
- Posted by: Harsh Piplani
- Category: Results
Jupiter Life Line Hospitals share price Rs 276.50 on 16 September 2026, up 0.34%. Q2 FY27 results date not confirmed. Q1 FY27 net profit Rs 38.00 crore. Q2 FY26 base a profit of Rs 57.00 crore.
Quick Answer
The Jupiter Life Line Hospitals Q2 results date for FY27 is not confirmed, and Jupiter Life Line Hospitals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published within 45 days of the quarter end, an outer deadline of 14 November 2026. The quarter will be measured against a September 2025 base of Rs 394.00 crore in revenue and a profit of Rs 57.00 crore. This preview uses reported actuals only and carries no estimated revenue or profit figure for the coming quarter.
The Jupiter Life Line Hospitals Q2 results FY27 announcement is the next scheduled earnings event for Jupiter Life Line Hospitals Ltd., Jupiter Life Line Hospitals Ltd. operates a chain of multi-specialty tertiary care hospitals in the Mumbai Metropolitan Region.. The stock traded at Rs 276.50 on the NSE on 16 September 2026, up 0.34% from the previous close of Rs 275.55, about 18.7% below its 52-week high of Rs 340.00 and 17.4% above its 52-week low of Rs 235.60.
What makes the Jupiter Life Line Hospitals Q2 results print worth watching is the base it faces. The September 2025 quarter delivered Rs 394.00 crore of revenue and a profit of Rs 57.00 crore, while the most recent quarter on record, Q1 FY27, produced Rs 411.00 crore and a profit of Rs 38.00 crore. Everything below is built from those reported figures rather than from any forecast.
Click Here – Get Free Investment Predictions
When Is the Jupiter Life Line Hospitals Q2 Results FY27 Date?
The Jupiter Life Line Hospitals Q2 results date for FY27 is not confirmed. As of 16 September 2026, Jupiter Life Line Hospitals Ltd. had not filed a board meeting intimation with the NSE or BSE for the September 2026 quarter, so any date circulating before that filing appears should be treated as unverified.
What can be stated is the regulatory boundary. Listed companies in India must publish quarterly results within 45 days of the end of the quarter, which places the outer deadline for the September 2026 quarter at 14 November 2026. Companies also have to give the exchanges prior intimation of the board meeting that approves the results, so the Jupiter Life Line Hospitals Q2 results date becomes public through that filing rather than through any advance announcement.
The Jupiter Life Line Hospitals Q2 results FY27 print covers 1 July 2026 to 30 September 2026. Small and mid-cap companies more often report in the second half of that window than in the first, so late October or early November is the range to watch for Jupiter Life Line Hospitals.
Jupiter Life Line Hospitals Q2 Results Expectations: What the Market Is Actually Tracking
No verified analyst estimate for the Jupiter Life Line Hospitals Q2 results FY27 quarter is in the public domain, so no revenue or profit figure should be assumed for Jupiter Life Line Hospitals. The Jupiter Life Line Hospitals Q2 results watchlist below is built from what the company has actually reported and disclosed.
Jupiter Life Line Hospitals Q2 results for the September 2026 quarter will be measured against a revenue trend that has moved steadily higher over the past year. Revenue rose from Rs 353 crore in Jun25 to Rs 394 crore in Sep25, eased slightly to Rs 365 crore in Dec25, and then climbed to Rs 388 crore in Mar26 and Rs 411 crore in Jun26. This steady climb from Rs 353 crore to Rs 411 crore across five quarters points to consistent patient volume and occupancy growth, a useful backdrop for Jupiter Life Line Hospitals Q2 results. Ahead of Jupiter Life Line Hospitals Q2 results, the Sep25 quarter, at Rs 394 crore, is the closest seasonal reference point for the September 2026 quarter. Jupiter Life Line Hospitals Q2 results will show whether this multi-quarter revenue growth trend continues into the second quarter of the new fiscal year.
Operating margin at Jupiter Life Line Hospitals held in a tight 22 to 23 percent band for four straight quarters before slipping in the most recent one, a shift relevant to Jupiter Life Line Hospitals Q2 results. OPM was 22 percent in Jun25, then 23 percent in each of Sep25, Dec25, and Mar26, before dipping to 19 percent in Jun26. Net profit moved from Rs 44 crore in Jun25 to Rs 57 crore in Sep25, Rs 42 crore in Dec25, Rs 50 crore in Mar26, and then down to Rs 38 crore in Jun26, the lowest of the five quarters. This Jun26 dip in both margin and profit likely reflects ramp-up costs tied to new hospital capacity and bed expansion, a common pattern for hospital chains scaling up, and it is the key data point to weigh going into Jupiter Life Line Hospitals Q2 results for the September 2026 quarter.
Jupiter Life Line Hospitals trades at a high PE of about 47.5 to 47.9 times with a book value of Rs 47.1, return on equity of 13.1 percent, return on capital employed of 14.8 percent, and a negligible dividend yield of 0.07 percent, a valuation profile that carries added weight ahead of Jupiter Life Line Hospitals Q2 results. The main data-quality point flagged in the screener notes is the Jun26 dip in both operating margin, down to 19 percent from a steady 22-23 percent band, and net profit, down to Rs 38 crore, the lowest of the five quarters, likely reflecting ramp-up costs from new hospital capacity rather than a demand issue. Given the stock’s high PE, this margin dip deserves scrutiny, since a growth-stage valuation leaves less room for a sustained slowdown, making Jupiter Life Line Hospitals Q2 results for the September 2026 quarter an important checkpoint. The negligible dividend yield is consistent with a company reinvesting in expansion rather than distributing cash.
Check Jupiter Life Line Hospitals Ltd. Live Fundamentals on the Univest Screener
Jupiter Life Line Hospitals Q2 Results Preview: The Q1 FY27 Actuals It Builds On
Jupiter Life Line Hospitals Ltd. reported revenue of Rs 411.00 crore in Q1 FY27, up 16.43% from Rs 353.00 crore in Q1 FY26, and a profit of Rs 38.00 crore at the net level, down 13.64% from Rs 44.00 crore in Q1 FY26. These are reported actuals, not estimates.
Sequentially, revenue was up 5.93% over the March 2026 quarter figure of Rs 388.00 crore, and net profit was down 24.00% from Rs 50.00 crore in Q4 FY26. Operating margin stood at 22.0% in Q1 FY27 against 23.0% in the September 2025 quarter, which is the comparison the Jupiter Life Line Hospitals Q2 results print will be read against.
Q2 FY26 Base: The Comparison Jupiter Life Line Hospitals Q2 Results FY27 Must Beat
Jupiter Life Line Hospitals Ltd. reported revenue of Rs 394.00 crore and a profit of Rs 57.00 crore in Q2 FY26, the September 2025 quarter. That is the year-ago base against which the September 2026 numbers will be judged, and it is the single most useful figure in this Jupiter Life Line Hospitals Q2 results preview.
Net profit in that base quarter was above the Rs 38.00 crore just reported for Q1 FY27, so the year-on-year comparison starts from a demanding level. Revenue of Rs 394.00 crore sits below the Rs 411.00 crore of the June 2026 quarter, which frames how much sequential movement the Jupiter Life Line Hospitals Q2 results print needs to show growth.
Jupiter Life Line Hospitals Quarterly Results Trend Over the Last Four Quarters
| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) |
|---|---|---|
| Q2 FY26 (Sep 2025) | 394.00 | 57.00 |
| Q3 FY26 (Dec 2025) | 365.00 | 42.00 |
| Q4 FY26 (Mar 2026) | 388.00 | 50.00 |
| Q1 FY27 (Jun 2026) | 411.00 | 38.00 |
Figures in brackets denote negative numbers. All four quarters above are reported actuals taken from the company’s exchange filings, and they are the only basis this Jupiter Life Line Hospitals Q2 results preview uses.
Revenue across those four quarters ranged from Rs 365.00 crore to Rs 411.00 crore, and net profit from Rs 38.00 crore to Rs 57.00 crore. That spread is the honest context for the Jupiter Life Line Hospitals Q2 results FY27 print, and it is why a single quarter should not be read as a trend on its own.
Key Factors That Could Shape Jupiter Life Line Hospitals Q2 Results FY27
The Jupiter Life Line Hospitals Q2 results outcome will turn on a small number of company-specific variables rather than on broad market conditions. The three below are the ones visible in what Jupiter Life Line Hospitals has already reported.
Valuation Snapshot
Jupiter Life Line Hospitals trades at a price-to-earnings multiple of around 47.5 times trailing earnings, with EPS of Rs 5.82 and a book value of Rs 47.1 per share, putting the price-to-book ratio at a high 5.87 times. Return on equity of 13.1 percent is reasonable but does not fully explain the premium PE, which appears to price in continued growth from capacity expansion. The dividend yield is negligible at 0.07 percent, typical for a growth-stage hospital company. These figures together describe a stock priced for future growth rather than current earnings.
Technical and Price Context
Jupiter Life Line Hospitals has a 52-week range from a low of Rs 235.6 to a high of Rs 340.0, and the current price near Rs 277 sits roughly in the lower-middle portion of that band. The stock trades below its 50-day moving average of Rs 305.82 but just above its 200-day moving average of Rs 274.39, suggesting near-term weakness against a still-intact longer-term trend. The relative strength index of about 25.78 points to oversold conditions, reflecting recent selling pressure following the Jun26 margin dip.
Balance Sheet and Payout
Jupiter Life Line Hospitals carries a debt-to-equity ratio of 0.38, a moderate and manageable level of borrowings for a hospital chain investing in new capacity and bed additions. This debt level gives the company reasonable flexibility to continue funding expansion without excessive reliance on external financing. On the payout side, the dividend yield of 0.07 percent is negligible, consistent with a growth-focused hospital operator that prioritises reinvesting cash into new facilities and bed capacity over shareholder distributions at this stage of its growth.
Jupiter Life Line Hospitals Q2 Results FY27: Share Price and Valuation Going Into the Print
Jupiter Life Line Hospitals share price today is Rs 276.50 on the NSE, up Rs 0.95 or 0.34% from the previous close of Rs 275.55 on 16 September 2026, ahead of the Jupiter Life Line Hospitals Q2 results announcement.
| Metric | Value (16 September 2026) |
|---|---|
| NSE Symbol | JLHL |
| Current Market Price | Rs 276.50 |
| 52-Week High | Rs 340.00 |
| 52-Week Low | Rs 235.60 |
| Market Capitalisation | Rs 9069 crore |
| PE Ratio | 47.47 |
| PB Ratio | 5.87 |
| EPS (TTM) | Rs 5.82 |
| Book Value per Share | Rs 47.10 |
| Debt to Equity | 0.38 |
| Return on Equity | 13.1% |
| 50-Day Moving Average | Rs 305.82 |
| 200-Day Moving Average | Rs 274.39 |
| RSI (14) | 25.78 |
The stock trades below its 50-day average of Rs 305.82 but above its 200-day average of Rs 274.39, with a 14-day RSI of 25.78. None of this is a view on where the shares go once the Jupiter Life Line Hospitals Q2 results are announced, and no price target is offered here.
Download the Univest iOS App or Univest Android App to track Jupiter Life Line Hospitals Ltd. live price and quarterly earnings updates.
What Investors Should Watch When Jupiter Life Line Hospitals Q2 Results Are Announced
Four lines carry most of the information in a company of this size, and reading them in order keeps the Jupiter Life Line Hospitals Q2 results print in proportion.
- Revenue against the Rs 394.00 crore reported in the September 2025 base quarter
- Net profit against a profit of Rs 57.00 crore in that same quarter
- Operating margin against 22.0% in Q1 FY27
- Any exceptional item, provision or one-off gain disclosed alongside the numbers
A one-off gain or provision can move the reported profit far more than operations do in a company this size, which is why the Jupiter Life Line Hospitals Q2 results announcement should be read together with the notes to the results rather than the headline alone.
Conclusion on Jupiter Life Line Hospitals Q2 Results FY27
The Jupiter Life Line Hospitals Q2 results date is not confirmed, and 14 November 2026 is the statutory outer limit rather than an expected date. Jupiter Life Line Hospitals Ltd. will make the schedule public through a board meeting intimation to the exchanges, and until then the September 2026 quarter can only be framed by what has already been reported.
On that basis the Jupiter Life Line Hospitals Q2 results FY27 print faces a base of Rs 394.00 crore in revenue and a profit of Rs 57.00 crore, with the most recent quarter having delivered Rs 411.00 crore and a profit of Rs 38.00 crore. No numerical estimate appears in this preview because no verified consensus figure exists for Jupiter Life Line Hospitals, and readers should treat any preview that supplies one with caution. Verify every figure against the company filing on release and consult a SEBI-registered advisor before acting on quarterly earnings.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Jupiter Life Line Hospitals Q2 Results FY27
What is the Jupiter Life Line Hospitals Q2 results date for FY27?
Ans. The Jupiter Life Line Hospitals Q2 results date for FY27 is not confirmed. Jupiter Life Line Hospitals Ltd. had not filed a board meeting intimation with the NSE or BSE as of 16 September 2026. Indian listing rules require the September 2026 quarter results to be published by 14 November 2026 at the latest.
What quarter do the Jupiter Life Line Hospitals Q2 results 2026 cover?
Ans. The Jupiter Life Line Hospitals Q2 results FY27 cover 1 July 2026 to 30 September 2026, known as the September 2026 quarter. Jupiter Life Line Hospitals Ltd. reports revenue, operating profit and net profit for that period, and the Jupiter Life Line Hospitals Q2 results filing also carries the notes to the accounts.
What were the Jupiter Life Line Hospitals Q1 FY27 results?
Ans. Jupiter Life Line Hospitals Ltd. reported revenue of Rs 411.00 crore in Q1 FY27 and a profit of Rs 38.00 crore at the net level. Revenue was up 16.43% versus Q1 FY26 and net profit was down 13.64% from Rs 44.00 crore in Q1 FY26.
What were Jupiter Life Line Hospitals Q2 FY26 results in the September 2025 quarter?
Ans. Jupiter Life Line Hospitals Ltd. reported revenue of Rs 394.00 crore and a profit of Rs 57.00 crore in Q2 FY26. Operating margin was 23.0%. Those figures form the base for the Jupiter Life Line Hospitals Q2 results FY27 comparison.
What are the main Jupiter Life Line Hospitals Q2 results expectations this quarter?
Ans. No verified analyst estimate is publicly available. The Jupiter Life Line Hospitals Q2 results expectations centre on revenue against the Rs 394.00 crore base, net profit against a profit of Rs 57.00 crore, operating margin against 22.0% in Q1 FY27, and any exceptional item disclosed with the numbers.
What is Jupiter Life Line Hospitals share price today ahead of the Q2 earnings?
Ans. Jupiter Life Line Hospitals share price is Rs 276.50 on the NSE as of 16 September 2026, up 0.34% from Rs 275.55. The stock is about 18.7% below its 52-week high of Rs 340.00 and 17.4% above its 52-week low of Rs 235.60, at a market capitalisation of Rs 9069 crore.
Is Jupiter Life Line Hospitals a good stock to buy before the Q2 results?
Ans. This article does not offer a buy, sell or hold recommendation on Jupiter Life Line Hospitals Ltd. The stock trades at a price-to-book ratio of 5.87 with a return on equity of 13.1%. Assess the reported numbers when they are released and consult a SEBI-registered financial advisor before making any decision.
